Cargando…

Approval, reimbursement and pricing of high-cost cancer medicines in Australia

Detalles Bibliográficos
Autor principal:	Vitry, Agnes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602342/ http://dx.doi.org/10.1186/2052-3211-8-S1-O9

Ejemplares similares

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Prices of oncology medicines in European countries, Australia and New Zealand
por: Vogler, Sabine, et al.
Publicado: (2015)

Impact of discounts on medicine prices
por: Schneider, Peter, et al.
Publicado: (2015)

Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region
por: Nguyen, Tuan A, et al.
Publicado: (2015)

The effect of reimbursement on MRgFUS treatment of uterine fibroids
por: Machtinger, Ronit, et al.
Publicado: (2015)

Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
por: van den Brink, Rinke
Publicado: (2014)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Impact of DRG reimbursement system on hospital efficiency: systematic review
por: Tabrizi, Hossein Moshiri
Publicado: (2012)

Predictors of orphan drug approval
por: Heemstra, Harald
Publicado: (2010)

Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
por: Lukačišinová, Anna, et al.
Publicado: (2015)

Differential pricing: solidarity at times of financial crisis
por: Macchia, Flaminia
Publicado: (2014)

The impact of billing/reimbursement structures on the integration of aSBI into primary care practice: implementation experiences at five different types of clinics
por: Hartje, Joyce, et al.
Publicado: (2015)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983)

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

“Drugs to avoid” to improve quality use of medicines: how is Australia faring?
por: Vitry, Agnes, et al.
Publicado: (2021)

Consumption and cost trends of EGFR TKIs: influences of reimbursement and national price negotiation
por: Wu, Di, et al.
Publicado: (2022)

Access to new cancer medicines in Australia: dispelling the myths and informing a public debate
por: Vitry, Agnes, et al.
Publicado: (2016)

Access to subsidised medicines, cost of medicines and health outcomes: exploring general practitioners' perceptions and experiences
por: Babar, Zaheer-Ud-Din, et al.
Publicado: (2015)

Medicines and the media: news reports of medicines recommended for government reimbursement in Australia
por: Robertson, Jane, et al.
Publicado: (2013)

Response to Michael Wonder’s comments on the article ‘Assessment of the therapeutic value of new medicines marketed in Australia’
por: Vitry, Agnes I
Publicado: (2013)

Assessment of the therapeutic value of new medicines marketed in Australia
por: Vitry, Agnes I, et al.
Publicado: (2013)

Role of Economic Evaluations on Pricing of Medicines Reimbursed by the Italian National Health Service
por: Russo, Pierluigi, et al.
Publicado: (2022)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
por: Santa-Ana-Tellez, Yared, et al.
Publicado: (2015)

Impact of delisting OTC medicines from reimbursement list
por: Chytilová, Petra, et al.
Publicado: (2015)

The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
por: Mordi, Dumebi O, et al.
Publicado: (2015)

From Noordwijkerhout to Bendigo: lessons learnt in developing a high risk foot clinic in regional Australia
por: Perrin, Byron, et al.
Publicado: (2013)

The adequacy of encephalitis surveillance for emerging infectious diseases in Australia
por: Durrheim, David N, et al.
Publicado: (2012)

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders
por: Wasir, Riswandy, et al.
Publicado: (2019)

Retrospective financial analysis of medicines reimbursement services in community pharmacy
por: Chitan, Elena
Publicado: (2015)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

The timelines for the price and reimbursement authorization in Italy 2018–2020
por: Gallo, Valentina, et al.
Publicado: (2022)

Quality management: the key to achievement for the BreastScreen Australia Programme
por: Muller, J
Publicado: (2004)

O350 Epidemiology and diagnosis of epidemic and avian influenza in Australia
por: Baleriola, C., et al.
Publicado: (2007)

Prevalence of asymptomatic Clostridium difficile colonization in tertiary hospital patients in Australia
por: Kanamori, L Furuya, et al.
Publicado: (2015)

Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
por: Spillane, Susan, et al.
Publicado: (2015)

OA01.03. Sample size and regions of principally achievable significance in cost effectiveness studies: an example of complementary medicine
por: Ostermann, T, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_8porcbm4t4tao7tqnemeg9felk